Tesofensine — what does the research say about a neurotransmitter-acting anorectic?

Most of today’s high-profile weight loss molecules – semaglutide, tirzepatide, retatrutide — works on the incretin axis. It affects one specific biochemical pathway: GLP-1 (and related) receptors. Tesofensine represents a completely different pharmacological route: inhibits the reuptake of three neurotransmitters at the same time – dopamine, norepinephrine and serotonin. A mechanism more similar to classic psychostimulants, but in a new generation version with a different pharmacokinetic profile and a different target therapeutic effect.

Tesofensine is a small organic molecule from the class of triple monoamine reuptake inhibitors (DA/NA/5-HT), originally developed by NeuroSearch in the context of neurodegenerative diseases (Alzheimer’s, Parkinson’s) and acquired by Saniona for repositioning in the treatment of obesity. The molecule is currently in Phase III clinical trials; commercially available research reagents are available as Research Use Only.

Regulatory Frame – A Critical Distinction

Tesofensine comes in two distinct legal statuses:

• as pharmaceutical candidate in phase III clinical trials conducted by Saniona in the treatment of obesity, with clinical protocols and full medical supervision
• as research reagent (Research Use Only) — a chemical substance for laboratory research on monoaminergic pharmacology and appetite regulation mechanisms

Tesofensine it is not a registered medicine in any major jurisdiction. This article describes the clinical literature and mechanism in an educational context. Products marked “tesofensine” in the research peptide catalog operate under the RUO framework – without protocols of use, without dosage suggestions and without intended use for human consumption.

What is tesofensine – origin and pharmacological class

Tesofensine (chemical code NS2330) is a small organic molecule with a molecular weight of approximately 333 Da, developed in the 1990s by a Danish biotechnology company NeuroSearch. The original clinical goal was Alzheimer’s disease — the hypothesis assumed that simultaneous inhibition of the uptake of three neurotransmitters (DA, NA, 5-HT) could modulate cognitive deficits and depressive symptoms accompanying dementia. Later research in Parkinson’s disease were intended to test the potential to improve motor function and mood in patients with progressive neurodegeneration.

The informal shorthand used for retatrutide in online searches is explained in a separate entry: the shorthand “reta”: terminology explained.

The results in both indications were negative — tesofensine has not shown sufficient clinical effectiveness in Alzheimer/Parkinson protocols to justify further development in these areas. An unexpected side signal in these studies, however, there was a consistent reduction in body weight among participants – an effect so pronounced that it attracted the attention of research teams studying the pharmacology of obesity.

In 2014, the rights to tesofensine were acquired by Saniona (Danish biotechnology company), which repositioned the molecule towards the treatment of obesity. Currently, tesofensine is found in phase III clinical trials in a program targeting obesity – with a planned regulatory filing in jurisdictions willing to approve a molecule with this mechanistic profile.

Chemical characteristics

Mechanism of action – three neurotransmitter pathways

Tesofensine is triple monoamine reuptake inhibitor (TRI) — a molecule that simultaneously inhibits three presynaptic transporters:

• DAT (Dopamine Transporter) – Dopamine reuptake
• NET (Norepinephrine Transporter) – noradrenaline reuptake
• SERT (Serotonin Transporter) – Serotonin reuptake

Reuptake inhibition increases the concentration of these neurotransmitters in the synaptic cleft in many regions of the central nervous system. Consequences for metabolic regulation and eating behavior:

Effect on the satiety center in the hypothalamus. Increased serotonin availability in the arcuate and paraventricular nucleus circuits promotes satiety signals and reduces spontaneous food intake. Classic anti-obesity serotonergic drugs (sibutramine, fenfluramine) used a similar mechanism – with the difference that tesofensine adds activity in the DA and NA pathway.

Impact on the reward system and appetitive motivation. Dopamine is a central transmitter of the reward system in the nucleus accumbens and the ventral tegmental area. Increased dopamine availability changes the calculation of the “motivational value” of food – which in some circuits may dampen the tendency to eat in response to emotional and situational cues.

Impact on energy expenditure. Norepinephrine activates thermogenesis in brown tissue and modulates the activity of the sympathetic nervous system. Increased NA availability promotes an increase in resting energy expenditure – an effect observed in metabolic studies with tesofensine (Sjödin 2010).

The mechanistic profile of tesofensine is therefore fundamentally different from incretins. Where GLP-1 (semaglutide) modifies gastrointestinal physiology and insulinotropic signaling, tesofensine modifies neurotransmission in CNS circuits responsible for appetite, satiety, motivation and energy expenditure. Full context of the incretin axis in article about the incretins GLP-1, GIP and glucagon; full class review in guide to GLP-1 peptides in metabolism studies.

Clinical Trial Status – TIPO Program and Phase III Status

Tesofensine’s clinical achievements include several phases of research – initially under the supervision of NeuroSearch (Alzheimer’s, Parkinson’s), later under the supervision of Saniona (obesity). The most important for current positioning remain obesity research.

TIPO-1 – the most powerful phase II study in obesity

TIPO-1 (Tesofensine in Phase II Obesity 1) – a randomized, double-blind, placebo-controlled phase II study, published in Lancet in 2008 by the Astrup team. Characteristic:

• Population: 203 obese patients (BMI ≥30)
• Duration: 24 weeks
• Doses: 0.25 mg, 0.5 mg, 1.0 mg daily vs. placebo
• Endpoints: body weight change, safety profile, hemodynamic parameters

TIPO-1 results:

• Body weight reduction in the 0.5 mg group: ~9.2% (vs ~2.0% in placebo)
• Body weight reduction in the 1.0 mg group: ~10.6% (vs ~2.0% in placebo)
• Safety profile: cardiovascular effects predominated (increase in heart rate and diastolic pressure)
• General tolerance: good in lower dose groups, acceptable in higher doses

This is one of the highest reported effects for monotherapy in the treatment of obesity outside the incretin class – weight reduction values similar to what was later documented for semaglutide (Wegovy) in STEP-1.

Other research in the program

Following TIPO-1, smaller follow-up studies have been conducted in the metabolic area (Sjödin 2010 – energy balance and satiety). Phase III under Saniona’s supervision is currently underway — with protocols in patient populations with obesity and metabolic syndrome.

Table: main studies on tesofensine

Tesofensine against incretins – two different ways of treating obesity

Tesofensine’s position becomes clear in direct comparison with the currently dominant class of drugs used to treat obesity – incretins. For a direct comparison of semaglutide with retatrutide, see comparison of mechanisms and clinical outcomes.

Research position: tesofensine represents an alternative pharmacological pathway to incretins, relevant to models in which incretin-based mechanisms are unavailable, poorly tolerated or ineffective. The mechanism profile (central reward system, appetite motivation) differs from the incretin profile (mainly periphery + satiety signal). Direct comparative data between tesofensine and semaglutide do not exist.

Safety and limitations from clinical trials

The safety profile of tesofensine—particularly at higher doses—is different from that of incretins and requires separate consideration.

Most frequently reported side effects (TIPO-1, dose 0.5–1.0 mg)

• Increase in heart rate (~7–8 beats/minute at 1.0 mg vs. placebo)
• Increase in diastolic pressure (several mmHg, statistically significant)
• Sleep disturbances, dry mouth
• Constipation
• Agitation/nervousness in isolated cases
• Mild nausea

Tesofensine’s monoaminergic profile – particularly activity on DAT and NET – translates into the actual load on the cardiovascular system. This is an important methodological and clinical limitation: patients with baseline hypertension, arrhythmia or coronary artery disease are excluded from studies on molecules of this class in traditional clinical protocols.

What research has not yet determined

• Long-term safety profile (>24 weeks in humans) – The longest published RCT is TIPO-1 with 24 weeks. Phase III data will cover longer observation horizons.
• Cardiovascular profile in a population with baseline risk factors — most studies were conducted in obese patients without significant CV diseases; extension to populations with baseline coronary artery disease or hypertension requires separate protocols.
• Withdrawal profile — maintaining body weight reduction after completing pharmacotherapy, risk of rebound effect.
• Drug interactions — especially with other serotonergic molecules (SSRIs, SNRIs, MAOIs) — theoretical risk of serotonin syndrome when combined.

⚠️ The security data described above comes from clinical trials on tesofensine as a pharmaceutical candidate in phase II/III. In the context of the RUO research reagent, the molecule is not intended for use in humans – Saniona’s clinical research protocols do not translate to the use of the reagent in laboratory research. For clinical questions regarding tesofensine, consult your physician, not your testing reagent supplier.

Frequently asked questions

Does tesofensine work for weight loss?

In the Phase II TIPO-1 clinical trial (Astrup 2008, Lancet) tesofensine administered at doses of 0.5–1.0 mg daily for 24 weeks was associated with a reduction in body weight of approximately 9–11% compared to approximately 2% in the placebo group. This is one of the highest reported effects in the treatment of obesity in monotherapy outside the incretin class. Phase III, under Saniona’s supervision, is ongoing and will produce data in larger populations and over a longer time horizon.

How is tesofensine different from semaglutide?

Mechanistically, completely. Semaglutide Is GLP-1 receptor monoagonist — modifies the incretin axis. Tesofensine is triple monoamine reuptake inhibitor (DA/NA/5-HT) — modifies neurotransmission in the CNS. The side effect profile also differs: semaglutide predominates with gastrointestinal effects, tesofensine with cardiovascular effects.

Is tesofensine safe?

The short-term Phase II safety profile of TIPO-1 is described as acceptable for the obesity indication – with significant observation of increases in heart rate and diastolic blood pressure, particularly at higher doses. This is a clinical limitation: patients with baseline cardiovascular disease were excluded from the studies. Long-term safety profile in humans (>24 weeks) remains an area of active research — Phase III will bring answers.

At what stage is the research on tesofensine?

Tesofensine is currently located in phase III clinical trials under the supervision of Saniona, with the indication of obesity. Previous studies (phase II TIPO-1, 2008) showed significant effectiveness in weight loss. Full Phase III results remain pending. Registration as a drug will require regulatory approval upon completion of the clinical program.

Is tesofensine a drug?

Currently – NO. Tesofensine is a pharmaceutical candidate in Phase III clinical trials, without registration as a drug in any major jurisdiction (EMA, FDA and others). In international trade, tesofensine functions as research reagent (Research Use Only) — a chemical substance for laboratory research on monoaminergic pharmacology. Registration status may change following the publication of Saniona’s Phase III results and regulatory decisions.

Related content in the knowledge base

Tesofensine belongs to the group of compounds studied in relation to non-incretin pathways. This group also includes other research substances acting on alternative metabolic axes: BAM-15 (mitochondrial uncoupler – a safer class compared to classic DNP), SLU-PP-332 (ERR panagonist – “exertion mimetic”), 5-amino-1MQ (NNMT inhibitor – modulation of NAD+ metabolism). Four different mechanisms, the same therapeutic target.

In contrast, the incretin group includes: semaglutide (mono GLP-1), tirzepatide (dual GLP-1/GIP), retatrutide (tri GLP-1/GIP/glucagon). Together, these two groups form a broad map of anti-obesity pharmacology.

Summary

Tesofensine is a triple monoamine reuptake inhibitor — an alternative pharmacological path to incretins in the treatment of obesity. A molecule developed by NeuroSearch for neurodegenerative diseases, repositioned by Saniona after observing a weight reduction signal in previous studies. Phase II TIPO-1 (Astrup 2008, Lancet) showed a ~10% weight reduction in 24 weeks. Phase III under Saniona’s supervision is underway.

The safety profile differs from that of incretins – cardiovascular effects predominate (increase in heart rate and blood pressure), not gastrointestinal effects. The long-term profile in humans remains an area of active investigation.

In the market for research reagents, tesofensine functions as Research Use Only reagent — a chemical substance for laboratory research on monoaminergic pharmacology and mechanisms of appetite regulation in the CNS. It is not a registered medicine, it is not a dietary supplement, and it is not intended for human use.

More articles from this cluster: all metabolic peptide articles.

Bibliography

1. Astrup A, Madsbad S, Breum L et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomized, double-blind, placebo-controlled trial
2. Sjödin A, Gasteyger C, Nielsen AL et al. (2010). The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
3. Hauser RA, Salin L, Juhel N, Konyago VL (2008). Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations
4. Bello NT, Zahner MR (2009). Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity
5. Axel AMD, Mikkelsen JD, Hansen HH (2010). Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of α1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat

Tesofensine in the One Peptides catalog functions only as a chemical reagent intended for laboratory tests (Research Use Only). NO is not a medicinal product, dietary supplement or food. The information in this article is educational in nature and describes the clinical literature regarding tesofensine as a pharmaceutical candidate in Phase III clinical trials under Saniona – does not constitute medical advice, does not encourage the use of the molecule in any way other than for research, and does not contain protocols of use for the end purchaser. For clinical questions regarding the molecule, consult your doctor.

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›